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to 20 mg/kg of anti-CD40L administered
every 2 to 4 weeks although the responses
are rarely durable. These abstracts,3-5 to-
gether with the study reported here, suggest
that CD40/CD40L blockade with IDEC-131/
E6040 is a potentially effective therapy for
refractory ITP through selective suppression
of autoreactive T cells to platelet antigens.
—Joseph Schwartz and
James B. Bussel
New York Blood Center and Weill Medical
College of Cornell University
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And a final message from
antithrombin
Much is now made of the finding that the
genome of the human is only somewhat
larger than that of the simplest of organ-
isms. Essentially then, all species are com-
posed of a similar array of constituent pro-
teins. What makes us special is not the
number of these proteins but the way evolu-
tion has adapted them to allow their func-
tion to vary from tissue to tissue. As hema-
tologists, we have been able to see exactly
how this happens through the advances over
the last decade in our understanding of the
molecular mechanisms of coagulation. It
turns out that thrombin is not just a passive
protease but an allosterically controlled
protein that changes its function from initi-
ator of coagulation in the arterial circulation
to anticoagulant when it binds to the endo-
thelium of the capillaries. Similarly, the
plasminogen activator inhibitor PAI-1,
which has a prime function in controlling
fibrinolysis, has evolved a series of complex
interactions that also affect tissue growth
and differentiation. PAI-1, as with other
serpins, traps its target protease with a
springlike movement of its reactive site,
which shifts from the exterior to the interior
of the molecule. This mechanism normally
occurs in serpins following proteolytic
cleavage of the reactive site, but with PAI-1
it can also occur spontaneously, without
cleavage of the loop, to give an inactive
latent form. The maintenance of PAI-1 in its
active form is due to its allosteric interac-
tion with a plasma protein vitronectin, but
vitronectin also competitively binds to a
range of cell surface integrins and activa-
tors. This leads to a series of complex mo-
lecular and cellular interactions that are well
described as cross-talking. An increasingly
recognized contributor to such interactions,
the mobile phones, so to speak, of cross-
talking, are the heparan proteoglycans, epit-
omized in hematology by the heparins.
Evolution has added yet another layer to
this complexity in the utilization of spent
coagulation factors as signals for a variety
of tissue responses. An example is the adap-
tation of a fragment of plasminogen to yield
endostatin, an inhibitor of angiogenesis. But
the most spectacular example of antiangio-
genesis came with the finding by O’Reilly
and others1 that spent forms of antithrombin
blocked angiogenesis in the mouse, with an
accompanying induction of tumor regres-
sion. Antithrombin can, like PAI-1, undergo
a conformational transition to latent and
cleaved forms, but what has puzzled the
field is how such minor rearrangements
could lead to such a remarkable suppression
of angiogenesis. An answer is provided here
in the paper of Zhang and colleagues (page
1185). They show that the latent and
cleaved, but not the native, forms of anti-
thrombin produce a down-regulation of the
gene for the proangiogenic proteoglycan,
perlecan. The effect is to decrease the cell
surface receptors for the growth factors that
stimulate angiogenesis. The importance of
this paper is in the completeness and cre-
dence it adds to the earlier findings of
O’Reilly et al. It opens up intriguing pros-
pects for biochemical, structural, and cel-
lular research. We really are beginning to
listen in to, as well as observe, the cross-
talk that underlies our biologic complexity.
—Robin Carrell
Cambridge Institute for Medical
Research UK
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Thrombosis down to the
vessel wall
Protein C is the major natural anticoagulant
and a complete deficiency leads to a severe
thrombotic tendency shortly after birth. It is
activated by thrombin when it is bound to
thrombomodulin on the endothelial surface.
Since thrombin is the central procoagulant,
this constitutes a strong regulatory system to
keep coagulation limited and localized. Ac-
tivated protein C (APC) inhibits coagula-
tion, in the presence of its cofactor protein
S, by proteolytic cleavage of procoagulant
factors Va and VIIIa. Reduced performance
of this system, such as in partial (heterozy-
gous) deficiencies of protein C or protein S,
or in an amino acid change at one of the
cleavage sites of factor V, as in factor V
Leiden, results in thrombophilia (ie, an in-
creased risk of venous thrombosis).
The endothelial protein C receptor
(EPCR), discovered in 1994, has been re-
ported to enhance the activation of protein
C by thrombin bound to thrombomodulin.1,2
It is logical to postulate that abnormalities
in this receptor play a role in the etiology of
venous thrombosis. Because the receptor is
bound to the endothelial cells of the blood
vessels, its function cannot be readily as-
sessed in vivo. However, a soluble form of
EPCR (sEPCR) can be measured in plasma,
which is probably a degradation product of
EPCR, but still has some of the functions of
EPCR, such as binding to protein C. Inter-
estingly, levels of sEPCR have a strikingly
bimodal distribution in plasma, suggestive
of single locus genetic control.3
Poor function of EPCR could cause
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